INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI
Investigation into ICU Medical: Pomerantz LLP is investigating potential securities fraud and unlawful business practices by ICU Medical, Inc. following a warning from the FDA regarding unauthorized changes to their infusion pump products.
Stock Price Impact: Following the FDA's warning, ICU's stock price dropped by 4.42%, closing at $130.68 per share on April 22, 2025.
Trade with 70% Backtested Accuracy
Analyst Views on ICUI
About ICUI
About the author
ICU Medical Announces Q4 2025 Earnings Release Schedule
- Earnings Release Schedule: ICU Medical will release its Q4 2025 earnings on February 19, 2026, at 4:00 p.m. ET, reflecting the company's ongoing innovation and development in the medical products sector.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 4:30 p.m. ET on the same day, providing an in-depth analysis of financial results aimed at enhancing investor understanding and confidence in the company's performance.
- Webcast Availability: The conference call will be simultaneously available via webcast, accessible through the company's website, ensuring transparency and availability of information, thereby enhancing interaction with investors.
- Company Background: ICU Medical is a global leader in infusion systems and high-value critical care products, committed to providing quality, innovation, and value to clinical customers worldwide, showcasing the company's leadership position in the healthcare industry.
ICU Medical to Present Innovative Products at 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: ICU Medical will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 1:30 PM PT, showcasing its innovations in medical products, which is expected to attract significant investor interest.
- One-on-One Meetings: The management team will also engage in one-on-one meetings on the same day, aiming to deepen connections with potential investors and foster future capital collaborations, enhancing the company's market presence.
- Live Webcast: The presentation will be webcast live on the company's website, allowing viewers to access and replay the session, which increases transparency and broadens its influence in the healthcare sector.
- Company Background: ICU Medical focuses on the development and sale of infusion systems and high-value critical care products, committed to providing quality and innovation to clinical customers worldwide, underscoring its leadership position in the medical industry.
Insiders Purchase Shares of VHT ETF Holdings
Insider Buying in Vanguard Health Care ETF: 17.6% of the weighted holdings in the Vanguard Health Care ETF (VHT) have seen insider buying in the past six months.
ICU Medical Inc Activity: ICU Medical Inc (ICUI), making up 0.05% of VHT, has had two directors and officers purchase shares recently, with the ETF holding $9,411,006 worth of ICUI.
Tandem Diabetes Care Inc Activity: Tandem Diabetes Care Inc (TNDM), the #243 largest holding in VHT, also shows insider buying from two directors and officers, with the ETF holding $3,407,114 worth of TNDM.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect those of Nasdaq, Inc.
Keybanc Keeps Overweight Rating on ICU Medical and Increases Price Target to $175
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform is designed to help traders win in the markets every day with accurate stock market intelligence.
After-Hours Surge in GMED, TNDM, ICUI, ORGO, SKIN, TXG Fueled by Q3 Results
Globus Medical Earnings Surge: Globus Medical's stock rose 24.37% after reporting a Q3 net income of $119 million and raising its 2025 revenue outlook to $2.86-$2.90 billion, with non-GAAP EPS guidance increased to $3.75-$3.85.
Tandem Diabetes Care Recovery: Tandem Diabetes Care's stock rebounded 20.03% after narrowing its Q3 net loss to $21.2 million and reaffirming its 2025 sales guidance of approximately $1 billion.
Organogenesis Holdings Growth: Organogenesis Holdings saw a 19.28% increase in stock price following a Q3 net income of $21.6 million and an updated 2025 revenue forecast of $500-$525 million.
ICU Medical and 10x Genomics Updates: ICU Medical's stock rose 14.14% after narrowing its Q3 net loss, while 10x Genomics advanced 8.92% despite a Q3 net loss, with both companies revising their 2025 guidance.
ICU Medical (ICUI) Set to Release Earnings Tomorrow: Key Insights to Anticipate
Earnings Report Overview: ICU Medical is set to report its earnings this Thursday, with analysts expecting a revenue decline of 13.3% year on year to $510.5 million, and adjusted earnings of $1.43 per share.
Previous Performance: Last quarter, ICU Medical exceeded revenue expectations by 1.7%, reporting $548.9 million, although this was an 8% decrease from the previous year.
Analyst Sentiment: Analysts have maintained their estimates for ICU Medical over the past month, indicating confidence in the company's performance, as it has only missed revenue estimates once in the last two years.
Market Context: Compared to peers like Merit Medical Systems and Intuitive Surgical, which reported strong revenue growth, ICU Medical's stock has seen a 3.5% increase over the past month, with an average analyst price target of $174.83 against its current price of $125.66.
ICU Medical Announces Q4 2025 Earnings Release Schedule
- Earnings Release Schedule: ICU Medical will release its Q4 2025 earnings on February 19, 2026, at 4:00 p.m. ET, reflecting the company's ongoing innovation and development in the medical products sector.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 4:30 p.m. ET on the same day, providing an in-depth analysis of financial results aimed at enhancing investor understanding and confidence in the company's performance.
- Webcast Availability: The conference call will be simultaneously available via webcast, accessible through the company's website, ensuring transparency and availability of information, thereby enhancing interaction with investors.
- Company Background: ICU Medical is a global leader in infusion systems and high-value critical care products, committed to providing quality, innovation, and value to clinical customers worldwide, showcasing the company's leadership position in the healthcare industry.
ICU Medical to Present Innovative Products at 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: ICU Medical will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 1:30 PM PT, showcasing its innovations in medical products, which is expected to attract significant investor interest.
- One-on-One Meetings: The management team will also engage in one-on-one meetings on the same day, aiming to deepen connections with potential investors and foster future capital collaborations, enhancing the company's market presence.
- Live Webcast: The presentation will be webcast live on the company's website, allowing viewers to access and replay the session, which increases transparency and broadens its influence in the healthcare sector.
- Company Background: ICU Medical focuses on the development and sale of infusion systems and high-value critical care products, committed to providing quality and innovation to clinical customers worldwide, underscoring its leadership position in the medical industry.
Insiders Purchase Shares of VHT ETF Holdings
Insider Buying in Vanguard Health Care ETF: 17.6% of the weighted holdings in the Vanguard Health Care ETF (VHT) have seen insider buying in the past six months.
ICU Medical Inc Activity: ICU Medical Inc (ICUI), making up 0.05% of VHT, has had two directors and officers purchase shares recently, with the ETF holding $9,411,006 worth of ICUI.
Tandem Diabetes Care Inc Activity: Tandem Diabetes Care Inc (TNDM), the #243 largest holding in VHT, also shows insider buying from two directors and officers, with the ETF holding $3,407,114 worth of TNDM.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect those of Nasdaq, Inc.
Keybanc Keeps Overweight Rating on ICU Medical and Increases Price Target to $175
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform is designed to help traders win in the markets every day with accurate stock market intelligence.
After-Hours Surge in GMED, TNDM, ICUI, ORGO, SKIN, TXG Fueled by Q3 Results
Globus Medical Earnings Surge: Globus Medical's stock rose 24.37% after reporting a Q3 net income of $119 million and raising its 2025 revenue outlook to $2.86-$2.90 billion, with non-GAAP EPS guidance increased to $3.75-$3.85.
Tandem Diabetes Care Recovery: Tandem Diabetes Care's stock rebounded 20.03% after narrowing its Q3 net loss to $21.2 million and reaffirming its 2025 sales guidance of approximately $1 billion.
Organogenesis Holdings Growth: Organogenesis Holdings saw a 19.28% increase in stock price following a Q3 net income of $21.6 million and an updated 2025 revenue forecast of $500-$525 million.
ICU Medical and 10x Genomics Updates: ICU Medical's stock rose 14.14% after narrowing its Q3 net loss, while 10x Genomics advanced 8.92% despite a Q3 net loss, with both companies revising their 2025 guidance.
ICU Medical (ICUI) Set to Release Earnings Tomorrow: Key Insights to Anticipate
Earnings Report Overview: ICU Medical is set to report its earnings this Thursday, with analysts expecting a revenue decline of 13.3% year on year to $510.5 million, and adjusted earnings of $1.43 per share.
Previous Performance: Last quarter, ICU Medical exceeded revenue expectations by 1.7%, reporting $548.9 million, although this was an 8% decrease from the previous year.
Analyst Sentiment: Analysts have maintained their estimates for ICU Medical over the past month, indicating confidence in the company's performance, as it has only missed revenue estimates once in the last two years.
Market Context: Compared to peers like Merit Medical Systems and Intuitive Surgical, which reported strong revenue growth, ICU Medical's stock has seen a 3.5% increase over the past month, with an average analyst price target of $174.83 against its current price of $125.66.
